These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 29401150)
21. Unusual Case of Diffuse Penile Metastasis of Prostate Cancer on 68Ga PSMA PET/CT Imaging and 177Lu PSMA Posttherapy Scintigraphy. Vadi SK; Kumar R; Mittal BR; Parihar AS; Singh SK Clin Nucl Med; 2018 Apr; 43(4):276-278. PubMed ID: 29465493 [TBL] [Abstract][Full Text] [Related]
22. Diagnostic Performance of 68Ga-PSMA-11 Positron-emission-tomography/Computed-tomography in a Large Cohort of Patients with Biochemical Recurrence of Prostate Carcinoma. Hoffmann MA; Buchholz HG; Wieler HJ; Müller-Hübenthal J; Trampert L; Richardsen I; Schreckenberger M Health Phys; 2020 Jul; 119(1):141-147. PubMed ID: 32301863 [TBL] [Abstract][Full Text] [Related]
23. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. Demirci E; Sahin OE; Ocak M; Akovali B; Nematyazar J; Kabasakal L Nucl Med Commun; 2016 Nov; 37(11):1169-79. PubMed ID: 27333090 [TBL] [Abstract][Full Text] [Related]
29. 68Ga-PSMA-Ligand PET/CT Uptake in Anthracosilicosis. McGuiness M; Sounness B Clin Nucl Med; 2017 Oct; 42(10):e431-e432. PubMed ID: 28806260 [TBL] [Abstract][Full Text] [Related]
30. 68Ga-PSMA PET/CT Imaging in Multiple Myeloma. Sasikumar A; Joy A; Pillai MR; Nanabala R; Thomas B Clin Nucl Med; 2017 Feb; 42(2):e126-e127. PubMed ID: 27941377 [TBL] [Abstract][Full Text] [Related]
31. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography? Kulkarni SC; Sundaram PS; Padma S Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366 [TBL] [Abstract][Full Text] [Related]
35. PET/CT With Giovacchini G; Giovannini E; Riondato M; Ciarmiello A Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673 [TBL] [Abstract][Full Text] [Related]
36. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132 [TBL] [Abstract][Full Text] [Related]
37. Optimal time-point for Beheshti M; Paymani Z; Brilhante J; Geinitz H; Gehring D; Leopoldseder T; Wouters L; Pirich C; Loidl W; Langsteger W Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1188-1196. PubMed ID: 29476228 [TBL] [Abstract][Full Text] [Related]
39. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer. Tulsyan S; Das CJ; Tripathi M; Seth A; Kumar R; Bal C Nucl Med Commun; 2017 Dec; 38(12):1094-1102. PubMed ID: 28957842 [TBL] [Abstract][Full Text] [Related]
40. Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma. Sahlmann CO; Meller B; Bouter C; Ritter CO; Ströbel P; Lotz J; Trojan L; Meller J; Hijazi S Eur J Nucl Med Mol Imaging; 2016 May; 43(5):898-905. PubMed ID: 26563122 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]